A large number of studies indicate that Potassium Voltage-Gated Channel Q4 (KCNQ4) gene is the cause of non-syndromic hearing loss, but there are few studies investigating the role of KCNQ4 in cancers and scarcity of comprehensive analysis of its involvement in the diagnosis, methylation, mutation, prognosis of various cancer types. Therefore, the aim of this study is to examine the anticancerous and immune effects of KCNQ4 in various cancers and its potential value in breast cancer. In this study, we explored the potential role of KCNQ4 in cancers using public databases and the R software for bioinformatics analysis. The results showed that the low expression of KCNQ4 across specific cancer types was positively associated with low mutation frequency and methylation, and the improved survival. Eight small molecule compounds were identified that could potentially target KCNQ4. In addition, immunohistochemistry confirmed that the KCNQ4 expression was low in breast cancer. In vitro experiments confirmed that overexpression of KCNQ4 inhibited cell migration and invasion and promoted apoptosis. In summary, our comprehensive pan-cancer analysis highlights the potential of KCNQ4 as a cancer marker, and can be used as an auxiliary prognostic indicator and an indicator for immunotherapy in certain tumor types.

大量研究表明钾电压门控通道Q4（KCNQ4）基因是非综合征性听力损失的病因，但目前很少有研究探讨KCNQ4在癌症中的作用，且缺乏对其在诊断中的综合分析、甲基化、突变、各种癌症类型的预后。因此，本研究的目的是探讨KCNQ4在各种癌症中的抗癌和免疫作用及其在乳腺癌中的潜在价值。在这项研究中，我们利用公共数据库和 R 软件进行生物信息学分析，探讨了 KCNQ4 在癌症中的潜在作用。结果表明，特定癌症类型中 KCNQ4 的低表达与低突变频率和甲基化以及生存率的提高呈正相关。鉴定出八种可能靶向 KCNQ4 的小分子化合物。此外，免疫组织化学证实KCNQ4在乳腺癌中表达较低。体外实验证实KCNQ4的过表达抑制细胞迁移和侵袭并促进细胞凋亡。总之，我们全面的泛癌分析凸显了 KCNQ4 作为癌症标志物的潜力，可用作辅助预后指标和某些肿瘤类型免疫治疗的指标。